Orchestra BioMed Holdings Inc OBIO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if OBIO is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $4.44
- Day Range
- $4.36–4.60
- 52-Week Range
- $4.22–20.19
- Bid/Ask
- $4.38 / $4.43
- Market Cap
- $157.06 Mil
- Volume/Avg
- 24,286 / 45,794
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 53.93
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the global commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- —
- Website
- https://www.orchestrabiomed.com
Comparables
Valuation
|
Metric
|
OBIO
|
ATEC
|
ANIK
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 2.36 | 22.71 | 1.77 |
Price/Sales | 53.93 | 3.20 | 2.25 |
Price/Cash Flow | — | — | 36.26 |
Price/Earnings
OBIO
ATEC
ANIK
Financial Strength
|
Metric
|
OBIO
|
ATEC
|
ANIK
|
|---|---|---|---|
Quick Ratio | 7.82 | 1.86 | 3.50 |
Current Ratio | 7.95 | 2.86 | 5.26 |
Interest Coverage | — | −10.23 | — |
Quick Ratio
OBIO
ATEC
ANIK
Profitability
|
Metric
|
OBIO
|
ATEC
|
ANIK
|
|---|---|---|---|
Return on Assets (Normalized) | −35.16% | −9.89% | −1.35% |
Return on Equity (Normalized) | −51.40% | — | −1.65% |
Return on Invested Capital (Normalized) | −50.12% | −9.94% | −2.24% |
Return on Assets
OBIO
ATEC
ANIK
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Cncphysz | Fnzp | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Qkbtyhfx | Qvykn | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Zrcpnryys | Jcsjsw | $97.8 Bil | |
MRNA
| Moderna Inc | Zmfjkxcjw | Pnf | $41.3 Bil | |
ARGX
| argenx SE ADR | Dwsqvgwp | Bcb | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Fwrwfxcn | Vjfc | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Txyzvmjc | Fcbnxqk | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Sjcgnkzjg | Mqntjqz | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Ynlkxdrmns | Llbjsp | $12.5 Bil | |
INCY
| Incyte Corp | Tckygmmr | Fclplkb | $11.6 Bil |